Dongyang Pharmaceutical said that its self-developed Tokumendong double insulin was approved for marketing to treat type 2 diabetes in adults. Dongyang Pharmaceutical became the second domestic pharmaceutical company to be approved for this type, and the number of insulin approved domestically increased to 7.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.